AxoGen Stock Price, News & Analysis (NASDAQ:AXGN) $7.15 +0.27 (+3.92%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$6.83▼$7.1750-Day Range$3.61▼$6.8852-Week Range$3.45▼$11.32Volume304,815 shsAverage Volume299,316 shsMarket Capitalization$307.74 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media AxoGen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside109.8% Upside$15.00 Price TargetShort InterestBearish5.33% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 4 Articles This WeekInsider TradingAcquiring Shares$62,200 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.58) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 starsMedical Sector471st out of 952 stocksMedical Devices Industry3rd out of 9 stocks 3.5 Analyst's Opinion Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, AxoGen has a forecasted upside of 109.8% from its current price of $7.15.Amount of Analyst CoverageAxoGen has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.33% of the float of AxoGen has been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in AxoGen has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AXGN. Previous Next 3.1 News and Social Media Coverage News SentimentAxoGen has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AxoGen this week, compared to 1 article on an average week.Search Interest2 people have searched for AXGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $62,200.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.21% of the stock of AxoGen is held by insiders.Percentage Held by Institutions83.77% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.58) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -12.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -12.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AxoGen Stock (NASDAQ:AXGN)AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Read More AXGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXGN Stock News HeadlinesDecember 1, 2023 | finance.yahoo.comCompany Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 1, 2023 | americanbankingnews.comAxoGen, Inc. (NASDAQ:AXGN) Sees Large Increase in Short InterestDecember 5, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 29, 2023 | americanbankingnews.comAxoGen (NASDAQ:AXGN) Lowered to "Hold" at StockNews.comNovember 20, 2023 | finance.yahoo.comAxogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare ConferenceNovember 17, 2023 | finance.yahoo.comGreat week for AxoGen, Inc. (NASDAQ:AXGN) institutional investors after losing 51% over the previous yearNovember 9, 2023 | morningstar.comAxogen Inc AXGNNovember 8, 2023 | marketwatch.comAxogen Shares Rise 34% After Narrower-Than-Expected 3Q LossDecember 5, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 8, 2023 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | finance.yahoo.comAxogen, Inc. Reports 2023 Third Quarter Financial ResultsNovember 7, 2023 | finance.yahoo.comAxogen Inc (AXGN) Reports 12% Revenue Growth in Q3 2023November 6, 2023 | msn.comAxoGen Q3 2023 Earnings PreviewOctober 18, 2023 | finance.yahoo.comAxogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023October 17, 2023 | msn.comLeerink Partners Initiates Coverage of Axogen (AXGN) with Outperform RecommendationSeptember 28, 2023 | finance.yahoo.comAxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?September 5, 2023 | finance.yahoo.comAxogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™August 23, 2023 | msn.comCantor Fitzgerald Reiterates Axogen (AXGN) Overweight RecommendationAugust 21, 2023 | finance.yahoo.comAxogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, OhioAugust 10, 2023 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN) Q2 2023 Earnings Call TranscriptAugust 8, 2023 | markets.businessinsider.comJMP Securities Remains a Buy on AxoGen (AXGN)August 8, 2023 | finance.yahoo.comAxogen, Inc. Reports 2023 Second Quarter Financial ResultsAugust 8, 2023 | finance.yahoo.comAxoGen (AXGN) Reports Q2 Loss, Lags Revenue EstimatesJuly 27, 2023 | finance.yahoo.comAxogen to Participate at Canaccord Genuity’s 43rd Annual Growth ConferenceJuly 26, 2023 | finance.yahoo.comAxogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023July 5, 2023 | fool.comAxoGen (NASDAQ: AXGN)June 10, 2023 | finance.yahoo.comWith 71% ownership, AxoGen, Inc. (NASDAQ:AXGN) boasts of strong institutional backingSee More Headlines Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXGN CUSIPN/A CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees394Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$20.00 Low Stock Price Target$9.00 Potential Upside/Downside+109.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,950,000.00 Net Margins-15.26% Pretax Margin-15.26% Return on Equity-23.44% Return on Assets-11.96% Debt Debt-to-Equity Ratio0.68 Current Ratio3.28 Quick Ratio2.42 Sales & Book Value Annual Sales$138.58 million Price / Sales2.22 Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book2.99Miscellaneous Outstanding Shares43,040,000Free Float39,941,000Market Cap$307.74 million OptionableOptionable Beta1.12 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMs. Karen Zaderej (Age 61)Chairman, President & CEO Comp: $852.18kMr. Peter J. Mariani (Age 59)Executive VP & CFO Comp: $532.5kMr. Michael Donovan (Age 58)Vice President of Operations Comp: $406.02kMr. Angelo G. Scopelianos Ph.D. (Age 68)Chief Research & Development Officer Comp: $540.91kEd JoyceDirector of Investor RelationsMr. Marc A. Began (Age 55)Executive VP, General Counsel & Chief Compliance Officer Ms. Doris QuackenbushVice President of SalesMr. Jens Schroeder KempChief Marketing OfficerMr. Erick DeVinney (Age 47)Vice President of Peripheral Nerve Science and Clinical Innovation More ExecutivesKey CompetitorsSemler ScientificNASDAQ:SMLROutset MedicalNASDAQ:OMZynexNASDAQ:ZYXIEdap TmsNASDAQ:EDAPFONARNASDAQ:FONRView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 3,408 shares on 11/24/2023Ownership: 0.060%Jacobs Levy Equity Management Inc.Bought 75,328 shares on 11/17/2023Ownership: 0.251%OLD National Bancorp INSold 8,770 shares on 11/17/2023Ownership: 0.028%Creative PlanningBought 18,908 shares on 11/16/2023Ownership: 0.044%Ameriprise Financial Inc.Sold 9,397 shares on 11/15/2023Ownership: 0.693%View All Insider TransactionsView All Institutional Transactions AXGN Stock Analysis - Frequently Asked Questions Should I buy or sell AxoGen stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares. View AXGN analyst ratings or view top-rated stocks. What is AxoGen's stock price target for 2024? 4 brokers have issued twelve-month price objectives for AxoGen's stock. Their AXGN share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 109.8% from the stock's current price. View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts. How have AXGN shares performed in 2023? AxoGen's stock was trading at $9.98 at the beginning of 2023. Since then, AXGN stock has decreased by 28.4% and is now trading at $7.15. View the best growth stocks for 2023 here. Are investors shorting AxoGen? AxoGen saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 2,160,000 shares, an increase of 33.3% from the October 31st total of 1,620,000 shares. Based on an average trading volume of 433,100 shares, the days-to-cover ratio is presently 5.0 days. Currently, 5.3% of the company's stock are sold short. View AxoGen's Short Interest. When is AxoGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024. View our AXGN earnings forecast. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) announced its earnings results on Tuesday, November, 7th. The medical equipment provider reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.08. The medical equipment provider earned $41.27 million during the quarter, compared to the consensus estimate of $40 million. AxoGen had a negative trailing twelve-month return on equity of 23.44% and a negative net margin of 15.26%. What ETF holds AxoGen's stock ? iShares Neuroscience and Healthcare ETF holds 5,003 shares of AXGN stock, representing 0.66% of its portfolio. What is Karen Zaderej's approval rating as AxoGen's CEO? 19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL). Who are AxoGen's major shareholders? AxoGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Tocqueville Asset Management L.P. (2.18%), Northern Trust Corp (0.94%), Ameriprise Financial Inc. (0.69%), Essex Investment Management Co. LLC (0.69%), Legal & General Group Plc (0.43%) and Acadian Asset Management LLC (0.42%). Insiders that own company stock include Amy Mcbride Wendell, Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Guido J Neels, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, Peter J Mariani and William P Mr Burke. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AXGN) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.